Sorafenib treatment on Chinese patients with advanced hepatocellular carcinoma: A study on prognostic factors of the viral and tumor status

Sorafenib is of proven efficacy in treating patients of hepatocellular carcinoma (HCC). Our study was aimed to determine the factors influence the sorafenib efficacy. We evaluated data of HCC patients receiving sorafenib from June 2012 to October 2016. All HCC cases were of the Barcelona Clinic Live...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Shou-Wu, Lee, Teng-Yu, Peng, Yen-Chun, Yang, Sheng-Shun, Yeh, Hong-Zen, Chang, Chi-Sen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
4500
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6946266/
https://www.ncbi.nlm.nih.gov/pubmed/31689794
http://dx.doi.org/10.1097/MD.0000000000017692

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6946266/
https://www.ncbi.nlm.nih.gov/pubmed/31689794
http://dx.doi.org/10.1097/MD.0000000000017692

Ejemplares similares